339 related articles for article (PubMed ID: 15103224)
41. Measurement of Ki-67 antigen in 159 pituitary adenomas using the MIB-1 monoclonal antibody.
Pizarro CB; Oliveira MC; Coutinho LB; Ferreira NP
Braz J Med Biol Res; 2004 Feb; 37(2):235-43. PubMed ID: 14762579
[TBL] [Abstract][Full Text] [Related]
42. High Ki-67 expression is associated with prolactin secreting pituitary adenomas.
Bălinişteanu B; Cîmpean AM; Ceauşu AR; Corlan AS; Melnic E; Raica M
Bosn J Basic Med Sci; 2017 May; 17(2):104-108. PubMed ID: 28432860
[TBL] [Abstract][Full Text] [Related]
43. Pituitary tumors in the elderly.
Kurosaki M; Saeger W; Lüdecke DK
Pathol Res Pract; 2001; 197(7):493-7. PubMed ID: 11482580
[TBL] [Abstract][Full Text] [Related]
44. Clinical and morphological characteristics, diagnostic criteria, and outcomes of surgical treatment of TSH-secreting pituitary adenomas.
Astaf'eva LI; Kadashev BA; Shishkina LV; Kalinin PL; Fomichev DV; Kutin MA; Aref'eva IA; Dzeranova LK; Sidneva YG; Klochkova IS; Rotin DL
Zh Vopr Neirokhir Im N N Burdenko; 2016; 80(6):24-35. PubMed ID: 28139570
[TBL] [Abstract][Full Text] [Related]
45. Plurihormonality of pituitary adenomas in light of immunohistochemical studies.
Pawlikowski M; Kunert-Radek J; Radek M
Endokrynol Pol; 2010; 61(1):63-6. PubMed ID: 20205106
[TBL] [Abstract][Full Text] [Related]
46. Pituitary macroadenomas (>3 cm) in young adulthood: Pathologic and proliferative characteristics.
Öngürü Ö; Düz B; Şimşek H; Günal A; Gönül E
Neurol Neurochir Pol; 2015; 49(4):212-6. PubMed ID: 26188936
[TBL] [Abstract][Full Text] [Related]
47. Determination of the proliferation and apoptotic index in adrenocorticotropin-secreting pituitary tumors : comparison between micro- and macroadenomas.
Losa M; Barzaghi RL; Mortini P; Franzin A; Mangili F; Terreni MR; Giovanelli M
Am J Pathol; 2000 Jan; 156(1):245-51. PubMed ID: 10623673
[TBL] [Abstract][Full Text] [Related]
48. The clinical and pathological significance of nitric oxide synthase in human pituitary adenomas: a comparison with MIB-1.
Onishi K; Kamida T; Momii Y; Abe T; Fujiki M
Endocrine; 2014 May; 46(1):154-9. PubMed ID: 24008756
[TBL] [Abstract][Full Text] [Related]
49. Effects of octreotide treatment on the proliferation and apoptotic index of GH-secreting pituitary adenomas.
Losa M; Ciccarelli E; Mortini P; Barzaghi R; Gaia D; Faccani G; Papotti M; Mangili F; Terreni MR; Camanni F; Giovanelli M
J Clin Endocrinol Metab; 2001 Nov; 86(11):5194-200. PubMed ID: 11701676
[TBL] [Abstract][Full Text] [Related]
50. Folliculo-stellate cells in pituitary adenomas of patients with acromegaly.
Voit D; Saeger W; Lüdecke DK
Pathol Res Pract; 1999; 195(3):143-7. PubMed ID: 10220793
[TBL] [Abstract][Full Text] [Related]
51. 'Silent' somatotropinoma.
Pawlikowski M; Kuta J; Fuss-Chmielewska J; Winczyk K
Endokrynol Pol; 2012; 63(2):88-91. PubMed ID: 22538745
[TBL] [Abstract][Full Text] [Related]
52. [Pituitary tumors: hormonal status and immunohistochemical evaluation].
Gołkowski F; Trofimiuk M; Buziak-Bereza M; Czepko R; Adamek D; Huszno B
Przegl Lek; 2003; 60(5):338-41. PubMed ID: 14593675
[TBL] [Abstract][Full Text] [Related]
53. Typical and atypical pituitary adenomas: a single-center analysis of outcome and prognosis.
Chiloiro S; Doglietto F; Trapasso B; Iacovazzo D; Giampietro A; Di Nardo F; de Waure C; Lauriola L; Mangiola A; Anile C; Maira G; De Marinis L; Bianchi A
Neuroendocrinology; 2015; 101(2):143-50. PubMed ID: 25633744
[TBL] [Abstract][Full Text] [Related]
54. The characteristics of incidental pituitary microadenomas in 120 Korean forensic autopsy cases.
Kim JH; Seo JS; Lee BW; Lee SY; Jeon SH; Lee KB
J Korean Med Sci; 2007 Sep; 22 Suppl(Suppl):S61-5. PubMed ID: 17923757
[TBL] [Abstract][Full Text] [Related]
55. Low aryl hydrocarbon receptor-interacting protein expression is a better marker of invasiveness in somatotropinomas than Ki-67 and p53.
Kasuki Jomori de Pinho L; Vieira Neto L; Armondi Wildemberg LE; Gasparetto EL; Marcondes J; de Almeida Nunes B; Takiya CM; Gadelha MR
Neuroendocrinology; 2011; 94(1):39-48. PubMed ID: 21178332
[TBL] [Abstract][Full Text] [Related]
56. Expression of corticotropin-releasing hormone messenger ribonucleic acid in human pituitary corticotroph adenomas associated with proliferative potential.
Xu B; Sano T; Yamada S; Li CC; Hirokawa M
J Clin Endocrinol Metab; 2000 Mar; 85(3):1220-5. PubMed ID: 10720066
[TBL] [Abstract][Full Text] [Related]
57. The quantitative evaluation of the immunohistochemical expression of the pituitary adenomas.
Kwinta BM; Grzywna E; Krzyżewski RM; Adamek D
Folia Med Cracov; 2017; 57(4):83-96. PubMed ID: 29337980
[TBL] [Abstract][Full Text] [Related]
58. Plurihormonal pituitary adenomas: immunostaining of all pituitary hormones is mandatory for correct classification.
Ho DM; Hsu CY; Ting LT; Chiang H
Histopathology; 2001 Sep; 39(3):310-9. PubMed ID: 11532042
[TBL] [Abstract][Full Text] [Related]
59. Multiple adenomas of the human pituitary. A retrospective autopsy study with clinical implications.
Kontogeorgos G; Kovacs K; Horvath E; Scheithauer BW
J Neurosurg; 1991 Feb; 74(2):243-7. PubMed ID: 1988594
[TBL] [Abstract][Full Text] [Related]
60. Adrenocorticotropic hormone secreting pituitary adenomas: analysis of growth fraction using the MIB-1 antibody.
Mastronardi L; Guiducci A; Spera C; Puzzilli F; Liberati F; Ruggeri A; Peciarolo A
Tumori; 2000; 86(3):229-32. PubMed ID: 10939604
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
